Evidence map›Paper›PMID 33995393›Full record

ArticleFrontiers in immunology2021

Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.

Poonam Suryawanshi, Rajani Bagul, Ashwini Shete, Madhuri Thakar

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Poonam SuryawanshiDeaprtment of Immunology and Serology, ICMR-National AIDS Research Institute, Pune, India.
Rajani BagulDeaprtment of Immunology and Serology, ICMR-National AIDS Research Institute, Pune, India.
Ashwini SheteDeaprtment of Immunology and Serology, ICMR-National AIDS Research Institute, Pune, India.
Madhuri ThakarDeaprtment of Immunology and Serology, ICMR-National AIDS Research Institute, Pune, India.
National AIDS Research Institute · INSymbiosis International University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Persistence of HIV reservoir even in suppressive ART is the key obstacle in HIV-1 cure. We evaluated the ability of HIV-1 C Env to reactivate the latently infected resting memory CD4 cells and the ability of polyclonal HIV antibodies mediating ADCC to lyse the reactivated targets. Methodology: HIV-1 antibodies from 25 HIV infected individuals (14 ADCC responders and 11 non-responders) were tested against the Env-C reactivated primary cells; CD4+ and CD4+CD45RO+ memory T cells in the presence of autologous or heterologous effector cells using multicolor flow cytometry. The frequencies of p24+ve target cells were measured to determine the reactivation and antibody mediated lysis. Results: Increase in the frequency of p24 expressing cells (P < 0.01 in all cases) after Env-C stimulation of target cells indicated reactivation. When these reactivated targets were mixed with effector cells and HIV-1 antibodies, the frequencies of p24 expressing targets were decreased significantly when the ADCC mediating antibodies (P < 0.01 in all cases) were added but not when the antibodies from ADCC non-responders or HIV negative individuals were added. In parallel, the NK cell activation was also increased only when ADCC mediating antibodies were added. Conclusion: The study showed that the HIV-1 Env could act as latency reversal agent (LRA), and only ADCC mediating antibodies could lyse the reactivated HIV reservoirs. The short stimulation cycle used in this study could be useful in testing LRAs as well as immune mediated lysis of reactivated reservoirs. The observations have further implication in designing antibody mediated immunotherapy for eradication of latent HIV reservoir.

Indexed as

AdultAntibody-Dependent Cell CytotoxicityAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusFemaleFlow CytometryHIV-1HIV AntibodiesHIV InfectionsHumansImmunologic MemoryLymphocyte ActivationMaleMiddle AgedAnti-HIV Agentsenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesADCCanti-HIV antibodiesHIVHIV Envlatent HIV

Identifiers

PMID33995393
PMCPMC8119992
OpenAlexW3157565235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.